36 / 74 · 0:54 · Original AXON film
ACE-031
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
ACE-031 | Investigational fusion protein
ACE-031 is an engineered fusion protein that binds myostatin and related signals. The goal was to investigate muscle disease, not to validate a bodybuilding product. [1]
HUMAN TRIAL | Duchenne muscular dystrophy
A randomized, placebo-controlled trial studied boys with Duchenne muscular dystrophy. Safety was the primary objective, alongside measurements related to body composition and physical function. [1]
Stopped early | Safety concerns
The study stopped early after safety concerns involving nosebleeds and widened small blood vessels. The reported walking-distance difference was not statistically significant. [1]
Function and safety must both matter
An experimental signal is not enough to establish useful muscle improvement. Safety and meaningful function have to be evaluated together before drawing treatment conclusions. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Campbell et al. (2017): Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial →Fusion-protein identity, DMD trial, early stopping and nonsignificant walking-distance finding.
